巴塞罗那大学研究团队发现，tirzepatide（商品名Mounjaro和Zepbound）除了能够抑制食欲外，还具有激活体内燃烧卡路里的棕色脂肪的作用1。这一发现表明该药物可能通过增加能量消耗来改善代谢，为其强大功效提供了新的解释1。
研究人员在肥胖小鼠模型（采用高脂肪饮食）中开展了实验，通过控制食物摄入来区分药物的直接代谢效应1。结果显示，tirzepatide激活棕色脂肪组织与代谢能量燃烧增加和batokines（对代谢有益的分子）产生增加相关联1。值得注意的是，该药物激活棕色脂肪的同时并未产生心脏不良副作用，反而显示出心血管益处1。
tirzepatide通过同时靶向GIP和GLP-1两个激素受体发挥作用1。然而，研究者Marion Peyrou指出需要谨慎看待这些发现："这是在小鼠上进行的研究，我们必须谨慎，因为物种之间在代谢调节、脂肪组织分布和药物反应方面可能存在显著差异"1。如果这一机制在人类中得到证实，将有助于指导开发更全面的肥胖症和糖尿病治疗方案1。
该研究已发表在《Biomedicine》期刊1。
Researchers at the University of Barcelona have discovered that tirzepatide, marketed as Mounjaro and Zepbound, can activate brown fat tissue in mice that burns calories and enhances metabolism beyond its appetite-suppressing effects.1 The medication targets two hormone receptors, GIP and GLP-1, simultaneously.1 In studies using obese mice on a high-fat diet, researchers controlled food intake to isolate the drug's direct metabolic effects.1 The activation of brown fat tissue was associated with increased energy expenditure and the production of batokines, molecules beneficial to metabolism.1
According to the findings, tirzepatide activated brown fat without producing adverse cardiac effects; in fact, the drug showed cardiovascular benefits.1 Marion Peyrou, one of the researchers, emphasized caution about extrapolating the results: "This is research conducted in mice, and we must be cautious because there may be significant differences between species in metabolic regulation, fat tissue distribution, and drug response."1 If confirmed in humans, the mechanism could help explain the drug's potent effectiveness and guide the development of more comprehensive treatments for obesity and diabetes.1 The study was published in Biomedicine in 2026, volume 195, with DOI: 10.1016/j.biopha.2026.119057.1
评论
还没有评论，欢迎留下第一条。